Myelofibrosis is a severe myeloproliferative neoplasm characterised by increased numbers of abnormal bone marrow megakaryocytes that induce progressive fibrosis, destroying the hematopoietic microenvironment. To determine the cellular and molecular basis for aberrant megakaryopoiesis in myelofibrosis, we performed high-throughput single-cell transcriptome profiling of 50,538 hematopoietic stem/progenitor cells (HSPCs), single-cell proteomics, genomics and functional assays. We identified an aberrant pathway for direct megakaryocyte differentiation from the earliest stages of hematopoiesis in myelofibrosis and associated aberrant molecular signatures, including surface antigens selectively expressed by JAK2-mutant HSPCs. Myelofibrosis megakaryocyte progenitors were heterogeneous, with distinct expression of fibrosis and proliferation-associated genes and putative therapy targets. We validated the immunoglobulin receptor G6B as a promising JAK2-mutant clone-specific antigen warranting further development as 2 an immunotherapy target. Our study paves the way for selective targeting of the myelofibrosis clone and more broadly illustrates the power of single-cell multi-omics to discover tumor-specific therapeutic targets and mediators of tissue fibrosis.
Introduction
Advances in single cell technologies have recently provided new insights into the cellular and molecular diversity and pathological mechanisms underlying many diseases, including cancers, premalignant and non-malignant conditions (Baslan and Hicks, 2017; Owen et al., 2018; Parikh et al., 2019) . Parallel interrogation of mutation status and transcriptome at a single-cell level provide unprecedented opportunity to identify cancer cell-specific targets (Giustacchini et al., 2017; Rodriguez-Meira et al., 2019) . Single cell resolution also uniquely enables identification of rare cell types and analysis of combinatorial patterns of gene expression, both of which are necessary to reconstruct differentiation trajectories and to accurately define cellular heterogeneity between populations such as normal and malignant tissues, as well as to identify the mediators of interactions between different cell types. For example, pathological fibrosis underlies many prevalent diseases including cancer, where fibrosis is well recognised to be important for disease progression and metastasis (Chandler et al., 2019; Cox and Erler, 2014) . It is broadly proposed that pro-fibrotic mediators secreted by cancer cells and infiltrating immune cells activate non-malignant stromal cells such as myofibroblasts to deposit collagen fibrosis (Cox and Erler, 2014) . However, an understanding of the specific cellular populations that mediate fibrosis in a given disease model, their molecular features, and the cellular pathways through which they are generated is necessary for these cells to be therapeutically targeted.
Myelofibrosis is a type of myeloproliferative neoplasms (MPNs) that results from somatic mutations in hematopoietic stem/progenitor cells (HSPCs) affecting MPL-JAK-STAT signaling, most commonly JAK2V617F (Kralovics et al., 2005; Levine et al., 2005) . Myelofibrosis is characterised by progressive bone marrow fibrosis which destroys the hematopoietic microenvironment, resulting in the cardinal disease features of cytopenias, mobilization of HSPCs to peripheral blood, extramedullary hematopoiesis, and a high propensity for leukemia. Survival is typically 5-10 years from diagnosis and is not substantially improved by currently available drug therapies (O'Sullivan and Harrison, 2018) . Megakaryocytes, the platelet-producing cells in the bone marrow, are dramatically increased 3 in number in myelofibrosis and are the key cellular drivers of the destructive bone marrow remodelling via excessive release of pro-fibrotic cytokines and growth factors (Ciurea et al., 2007; Eliades et al., 2011; Martyre et al., 1997; Wen et al., 2015) . In normal hematopoiesis, megakaryocyte progenitors (MkP) have a low proliferation rate, typically undergoing less than 8 cell divisions before mitotic arrest and the onset of polyploidization (Paulus et al., 2004) . However, the cellular and molecular pathways giving rise to the dramatically increased megakaryocyte numbers and megakaryocyte dysfunction leading to tissue fibrosis in myelofibrosis are unclear.
In traditional models of hematopoiesis, megakaryocytes are said to arise from a bipotent progenitor shared with the erythroid (red cell) lineage, the megakaryocyte-erythroid progenitor (MEP) (Akashi et al., 2000; Debili et al., 1996; Kondo et al., 1997; Manz et al., 2002; Pang et al., 2005; Psaila et al., 2016; Psaila and Mead, 2019; Sanada et al., 2016) . Recent advances in single-cell technologies including single-cell transplantation and lineage tracing studies of unperturbed hematopoiesis have revealed that hematopoiesis occurs over a continuum rather than via distinct, oligopotent intermediate steps (Laurenti and Gottgens, 2018; Psaila and Mead, 2019; Velten et al., 2017) , and also that a proportion of HSCs, at least in the murine system, are megakaryocyte-biased but retain capacity for multilineage reconstitution (Adolfsson et al., 2005; Benz et al., 2012; Carrelha et al., 2018; Rodriguez-Fraticelli et al., 2018; Sanjuan-Pla et al., 2013; Shin et al., 2014) . Lineage-committed megakaryocytes arising directly from HSCs, sometimes without cell division, have also been reported (Notta et al., 2016; Roch et al., 2015) .
Targeting megakaryocytes in myelofibrosis has been shown to ameliorate the disease in mouse models and early-phase human studies (Eliades et al., 2011; Wen et al., 2015) , but technical challenges have precluded extensive study of the cellular/molecular pathways for megakaryopoiesis in myelofibrosis. These include the rarity of megakaryocytes in the bone marrow, gaps in our knowledge of the cellular pathways of megakaryopoiesis and their extreme cell size and fragility. In addition, the severe fibrosis typically prevents bone marrow aspiration ("dry tap" aspirate).
However, bone marrow HSPCs are mobilized to the peripheral blood in myelofibrosis. In this study, we utilized this phenomenon to capture peripheral blood HSPCs and perform the first in-depth study of abnormal megakaryocyte differentiation and function in myelofibrosis, suggesting novel cellular and molecular targets. Using multiparameter immunophenotyping, functional studies, highthroughput single cell transcriptome profiling (scRNAseq), targeted single cell mutational analysis with simultaneous scRNAseq (TARGET-Seq (Rodriguez-Meira et al., 2019) ) and single cell proteomics we identify new potential targets for the inhibition of pathological megakaryocyte differentiation 4 and megakaryocyte-induced fibrosis and validate G6B as a cell surface marker that may enable specific ablation of myelofibrosis cells using immunotherapy. This study illustrates the power of single cell 'multi-omics' in the characterisation of cellular heterogeneity in cancers associated with aberrant fibrosis, including the identification of novel therapeutic pathways and cancer cell-specific targets.
Results

Analysis of mobilized HSPCs demonstrates megakaryocyte-biased HSCs in myelofibrosis
Multiparameter flow cytometric analysis of the CD34 + lineage (lin) -HSPC compartment in peripheral blood samples from healthy mobilized apheresis donors and patients with myelofibrosis (Suppl. Table 1 ) was performed to compare frequencies of the classically-defined HSPC subsets ( Figure 1A ).
This demonstrated reduced lymphoid-primed multipotent progenitors (LMPP) and increased multipotent progenitors (MPP, Fig. 1A ). The cell surface antigen CD41 has previously been reported to identify cells primed for megakaryocyte differentiation (Gekas and Graf, 2013; Haas et al., 2015; Psaila et al., 2016; Yamamoto et al., 2013 (Fig. 1D) .
In comparison to those from healthy donors, CD41 -HSC/MPP cells from myelofibrosis patients showed significant megakaryocyte vs. erythroid bias (Fig 1E) , in keeping with the clinical phenotype of myelofibrosis patients in which excessive megakaryocyte numbers occur in parallel with anemia.
In single-cell clonogenic assays supportive of myeloid and erythroid (but not megakaryocytic) colony formation (methocult), CD41 + and CD41 -fractions of HSC and MPP gave rise to expected colony frequencies with no significant difference between healthy donors and myelofibrosis patients (Suppl. Fig. S1C ). Together, these results support that in myelofibrosis, HSPCs are biased towards megakaryocyte-lineage differentiation from the earliest stem cell compartment, before expression of canonical megakaryocytic markers.
High-throughput single cell RNA-sequencing identifies a distinct pathway for megakaryocyte differentiation in myelofibrosis
To identify the cellular and molecular basis for megakaryocyte-biased hematopoiesis in myelofibrosis without bias from pre-selected cell surface antigens, high-throughput scRNAseq was performed on 48,421 individual CD34 + lin -HSPCs from patients with JAK2V617F+ post-polycythaemia myelofibrosis (30,088 cells, n=3) according to WHO criteria (Arber et al., 2016) and age-matched healthy donors (18,333 cells, n=2) using the 10x Genomics Chromium platform (Suppl. Table 2 ).
Following filtering, quality control and exclusion of doublets, 47,804 cells passed quality control (29,536 myelofibrosis and 18,249 control, Suppl. Table 3 ). Healthy donor control and myelofibrosis cells were aggregated separately and the donor effect was regressed out (Suppl. Fig. S1D ).
Dimensionality reduction and unsupervised clustering were performed using a uniform manifold approximation and projection (UMAP) method combined with k-means clustering to enable identification of distinct cell populations while preserving inter-cluster relationships (Becht et al., 2018) , Fig 2A) . Clusters were identified by analysis of differentially expressed genes for each cluster ( Fig. 2A , Suppl. Figs. S1E & 2, Suppl. Tables 4, 5 ). "Lineage signature gene sets" were then defined containing genes selectively associated with erythroid, myeloid, lymphoid and megakaryocyte lineages (Suppl. Fig. S2 , Suppl. Table 6 ) and superimposed on the UMAPs (Fig. 2B ). This highlighted 6 two distinct clusters of cells expressing megakaryocyte signature genes among myelofibrosis CD34 + lin -HSPCs, accounting for around 15% of the HSPCs overall. In contrast, very few healthy donor control HSPCs expressed megakaryocyte lineage signature genes and did not form a distinct cluster but were scattered within the erythroid cluster ( Fig. 2B (inset) , Suppl. Fig. S1E ).
To study differentiation trajectories, cells were ordered in gene expression space using forced directed graphs and lineage signature gene scores superimposed on the graphs (Fig. 3A) . Myeloid, erythroid and lymphoid trajectories were observed in both healthy donors and myelofibrosis patients. Expression of megakaryocyte genes (purple) was observed along a distinct trajectory arising directly from uncommitted HSPCs (grey) in addition to along the erythroid trajectory (red) only in myelofibrosis HSPCs (Fig. 3A & Fig. 3C ). Together with functional data (Fig. 1) , these data suggest a model in which a direct route for MkP production from HSPC is massively expanded in JAK2V617F mutation positive myelofibrosis, in addition to increased production of megakaryocytes via a shared trajectory with the erythroid lineage (Fig. 3B, Fig. 3D ).
Identifying molecular drivers for aberrant megakaryopoiesis in myelofibrosis
To identify potential molecular drivers for the aberrant megakaryocyte differentiation trajectory, we performed unsupervised k-means clustering on a 3-dimensional k-nearest neighbor (KNN) graph aggregate of all 47,804 cells (see .html file, Suppl. Item 1) and identified the paths taken by cells from the earliest undifferentiated HSPCs along the aberrant megakaryocyte trajectory that comprised almost entirely of myelofibrosis cells and the erythroid/megakaryocyte trajectory containing both myelofibrosis and control cells (Fig. 4A ). Expression patterns of 1,639 human transcription factors (Lambert et al., 2018) were examined along the two trajectories and genes clustered according to patterns of change in gene expression levels. Transcription factor genes showing progressive changes, either increased or decreased expression, along the two trajectories were further inspected (Suppl. Figs. S3, S4) and compared between the two trajectories ( Fig. 4B ).
Expected patterns of expression of transcription factors known to be involved in megakaryocyte and erythroid differentiation were observed (e.g. progressive increase in GATA1, GATA2), as well as antagonistic expression of two key regulators of megakaryocyte-erythroid cell fate decision FLI1 and KLF1 (Bouilloux et al., 2008; Dore and Crispino, 2011; Frontelo et al., 2007; Palii et al., 2019; Siripin et al., 2015) (Fig. 4B, 4C ). Additional genes not previously implicated as regulators of megakaryocyte vs.
erythroid differentiation showed striking differential expression between the trajectories, included YBX1, PLEK, SOX4 and MYC (Fig. 4B, 4C ), suggesting additional novel targets for strategies to specifically inhibit pathological megakaryopoiesis while preserving erythropoiesis in myelofibrosis patients.
Identifying mediators of megakaryocyte-induced fibrosis
To evaluate the pathological role of the expanded population of MkP in driving bone marrow fibrosis, we next examined potential mediators of fibrosis. Fibrosis regulators were identified from previously published datasets studying lung and liver fibrosis as well as bone marrow fibrosis (Allen et al., 2017; Blackman et al., 2013; Corvol et al., 2015; Gu et al., 2009; Mondet et al., 2015; Mushiroda et al., 2008; Noth et al., 2013; Ulveling et al., 2016; Wattacheril et al., 2017; Wright et al., 2011) . Genes detected at expression levels over 1 (using log-transformed UMI) were selected for a 'fibrosis signature' gene score (Suppl. Table 6 ). Superimposition of this score on the UMAPs for healthy donor and myelofibrosis HSPCs clearly highlighted the myelofibrosis MkP cluster cells (Fig.   5A ). All healthy donor and myelofibrosis cells expressing at least two megakaryocyte signature genes were then extracted for further analyses. Importantly, TGFB1 was detected both in a higher fraction of myelofibrosis MkP than healthy donor MkP (58.6% vs. 36.5%) and also expressed at substantially higher levels per cell (Fig. 5B ). This indicates that megakaryocyte-induced fibrosis in myelofibrosis is due to an aberrant pro-fibrotic megakaryocyte phenotype in addition to increased megakaryocyte numbers, an observation which would not have been possible without single-cell analysis. LTBP1, which encodes a protein that targets the latent form of transforming growth factor beta (TGFb) and contributes to its activation (Robertson et al., 2015) , showed a similar pattern with expression detected in a substantially higher % of myelofibrosis MkP as well as increased expression per cell (Fig. 5B) .
Normal megakaryocytes have a low proliferation index and healthy donor MkP showed low expression of the proliferation marker MKI67 (detected in only 6% of control MkP). By contrast, MKI67 was detected in >30% of myelofibrosis MkP and the MkP cluster showed highest expression of MKI67 among all myelofibrosis lineage clusters (Fig. 5B , Suppl. Fig. S5A ) as well as enrichment of a G2M checkpoint gene signature (Suppl. Fig. S5B , Suppl. Table 7 ), suggesting that increased proliferation of MkP may contribute to the pathological accumulation of megakaryocytes in myelofibrosis, in addition to Mk-biased hematopoiesis.
Myelofibrosis MkP demonstrate molecular heterogeneity with differential expression of proliferation and fibrosis genes
To identify distinct subpopulations of myelofibrotic MkP (MF-MkP), unsupervised clustering using Louvain community detection based on the KNN-weighted graph was performed on cells within the dominant Mk cluster (MkP2) from the myelofibrosis aggregate UMAP (Fig.2B , Suppl. Table 5 ). Seven sub-clusters were identified with distinct expression of fibrosis and proliferation-associated genes (Fig. 5C , Suppl. Fig. S5C ). Genes encoding key mediators of fibrosis (TGFB1 and CXCL2) were most highly expressed in MF-MkP clusters 1 -5, whereas MF-MkP clusters 4 -6 showed highest expression of proliferation markers MKI67 and TOP2A and an G2M gene signature (Fig. 5C , Suppl.
Fig . S5D ). AURKA emerged as selectively expressed in clusters 6 and 4, with particularly high expression in the minor cluster 6 ( Fig 5C) . This is of interest as AURKA is the target for alisertib (MLN8237), recently demonstrated to promote megakaryocyte polyploidization and ameliorate the myelofibrosis phenotype in mouse models (Wen et al., 2015) , with some efficacy also in patients with myelofibrosis (Gangat et al., 2019) .
Identifying myelofibrosis clone-specific cell surface targets
Increased expression of megakaryocyte genes in the myelofibrosis aggregate was noted to occur not just within the MkP cluster but also within clusters of uncommitted HSPCs and other lineageaffiliated clusters (Fig. 6A ). This included intracellular proteins (VWF and PF4) and also cell surface
antigens (ITGAB1 [CD41] and C6orf25 [G6B]).
Increased expression of C6orf25, encoding the G6B protein, was particularly striking (Fig. 6A ). G6B is an immunoreceptor tyrosine-based inhibition motif (ITIM)-containing inhibitory immune receptor, considered to be exclusively expressed on mature megakaryocytes in normal hematopoiesis (Coxon et al., 2017; Senis et al., 2007) . As the vast majority of healthy donor CD34 + lin -HSPCs did not express megakaryocyte genes, and because mature megakaryocytes normally lose expression of CD34 during differentiation (Tomer, 2004) , we hypothesized that aberrant co-expression of stem/progenitor and megakaryocyte surface antigens may enable selective identification of myelofibrosis clone-derived HSPCs.
Patients with myelofibrosis have distinct genetic subclones of HSPCs, including residual wild-type (non-mutated) as well as clones with co-mutations in addition to driver mutations (JAK2V617F or mutCALR). To determine whether the increase in expression of megakaryocyte-associated genes was specific to mutant clone HSPCs or due to cell-extrinsic signals affecting both mutated and unmutated 6D ). Further, in two patients with 3+ comutations in addition to the driver JAK2V617F mutation, the increase in G6B was observed in all genetic sub-clones detected (Suppl. Fig. S6 ).
Expression of cell surface G6B protein selectively identifies mutant clone derived HSPCs in myelofibrosis
High-throughput, single-cell proteomics by mass cytometry time of flight (CyTOF) was performed to enable simultaneous measurement of 20 surface proteins in multiple samples in parallel using barcode multiplexing (Fig. 7A , Suppl. Table 8 ). G6B was consistently detected at substantially higher levels in patients with primary and secondary myelofibrosis and with JAK2V617F and mutCALR driver mutations than in healthy donors ( Fig. 7A, 7B ). In addition, high cell surface G6B expression was also detected exclusively on JAK2V617F-mutated MPN cell lines (HEL, SET2) and not on the other leukemia cell lines K562, HL60, JURKAT and MARIMO and HEK human embryonic kidney cells (Suppl. To examine G6B expression in bone marrow megakaryocytes in situ, immunohistochemical staining was performed on trephine biopsy sections from healthy donors and patients with mutCALR and JAK2V617F+ myelofibrosis, confirming expected expression on control megakaryocytes but with a dramatic increase in G6B+ cells in myelofibrosis (Fig. 7C ).
Finally, to validate G6B as a potential target for therapies directed exclusively to mutant clone derived HSPCs, G6B positive and negative cells were FACS-isolated from healthy donor and myelofibrosis patient MNCs and expression of mutant vs. wild-type JAK2 determined by quantitative real time PCR (Moliterno et al., 2006) . Strikingly, expression of mutant JAK2V617F was almost exclusively restricted to G6B positive cells (Fig. 7D) . Together, these data identify G6B as a promising cell surface antigen to selectively target the aberrant megakaryocytic differentiation seen in myelofibrosis HSPCs.
Discussion
Bone marrow transplant is currently the only potentially curative treatment for myelofibrosis, but is associated with significant risk and the vast majority of patients are ineligible due to age and comorbidities. The introduction of JAK inhibitors has led to significant improvement in symptomatic management, but the majority of patients continue to experience substantial morbidity and a significant reduction in life expectancy. New approaches to treatment are urgently required.
Megakaryocytes are well recognized as the key cellular drivers of disease pathogenesis (Malara et al., 2018) , however only one megakaryocyte-targeting therapy -alisertib, a specific inhibitor of certain megakaryocyte surface antigens, in particular G6B, are markedly over-expressed in mutant clone-derived HSPCs compared with wild-type HSPCs from myelofibrosis patients or healthy donor
HSPCs. This validates combinatorial targeting of stem cell (e.g. CD34) and megakaryocyte (e.g. G6B)
surface antigens e.g. with bispecific antibody therapies as a potential strategy worthy of further investigation for selective ablation of the myelofibrosis clone. As none of the currently available treatments for myeloproliferative neoplasms reliably induce clonal remissions or substantially reduce fibrosis, this work sets the stage for immunotherapeutic targeting of aberrant hematopoiesis in myelofibrosis. Furthermore, the approach we have adopted and the resulting insights are highly relevant to other studies seeking to identify cancer cell-specific drug targets and cancer-associated fibrosis in other malignancies, as well as non-malignant disorders of tissue fibrosis.
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Methods
CONTACT FOR REAGENT AND RESOURCE SHARING
In vitro liquid culture differentiation assays
Cells were isolated by FACS into 1.5 µL eppendorfs, centrifuged at 500G for 5 minutes, resuspended in 100ul culture medium and plated in flat-bottom 96-well plates (Corning). Media used was Stemspan SFEM (StemCell Technologies #09650) + 1% Pen/Strep supplemented with recombinant human cytokines (Peprotech). Cells were analysed by FACS on days 6 and 14 (50 µl removed and replaced with fresh media).
Cytospins and MGG
Cells were FACS-isolated into 1.5ml Eppendorf tubes, centrifuged and resuspended into 200 µl PBS and cytospun at 500RPM for 5 minutes onto Superfrost glass slides. May Grunewald Giemsa stain was prepared as per manufacturers protocol, filtered and slides stained in May-Grunewald for 7 minutes followed by 20 minutes in Giemsa then washed in distilled water, air dried and coverslip applied.
Methocult assay
Single cells were FACS-isolated into flat bottomed 96-well plates containing 100 µl of MethoCult TM H4435 Enriched (StemCell Technologies Cat#04435). Colonies were visually inspected and classified 11-14 days after plating. Lineage assignment was made by morphological assessment with verification of ambiguous colonies by plucking and FACS analysis.
High-throughput single-cell RNA-sequencing (10X Chromium)
Cells were thawed, stained with FACS antibodies and sorted on an Aria III as described above and as per recommendations in the 10x Genomics Single Cell Protocols -Cell Preparation Guide. 15,000
CD34+ lineage negative cells were sorted into 20 µL PBS/0.05% BSA (non-acetylated) and then the cell number/volume adjusted to a target of 10,000 cells in 38 µL for loading onto the 10X Chromium
Controller. Samples were processed according to the 10x protocol using the Chromium Single Cell 3'
library & Gel Bead Kit v2 (10x Genomics). In summary, cells and reagents were prepared and loaded onto the chip and into the Chromium Controller for droplet generation. RT was conducted in the droplets and cDNA recovered through demulsification and bead purification. Pre-amplified cDNA was used for library preparation, multiplexed and run on a MiSeq using MiSeq Nano Reagent Kit V2 (Illumina Cat#102-2001) . CellRanger was used to estimate the number of cells, and samples then sequenced on a HiSeq 2500 using v4 chemistry to obtain 40-50,000 reads per cell.
TARGET-Seq
High-sensitivity single cell mutation analysis and parallel RNA-sequencing was performed as previously described (Rodriguez-Meira et al., 2019) . Counts were downloaded from GSE122198 , normalized by library size and log2-transformed as previously described (Rodriguez-Meira et al., 2019) . Cells were classified into WT-normal (cells from normal donors), WT-patient (non-mutant cells present in patient samples) and mutant (cells from patient samples carrying mutations in the genes targeted).
RNA sequencing of 'mini-bulk' HSPC populations
100 cells from each population were isolated by FACS into 4 µl of lysis buffer containing oligo-dT primer and dNTP mix in 0.2 mL PCR tubes. Cell lysis, RT and PCR preamplification and purification was performed using the Smart-Seq 2 protocol as previously published (Picelli et al., 2014) . Libraries were pooled and tagmentation performed using the Illumina Nextera XT DNA sample preparation kit (Illumina Cat #FC-131-1024), libraries pooled and sequenced on a HiSeq 2000.
Antibody labelling with metal conjugates and mass cytometry (CyTOF)
Antibodies were purchased pre-conjugated when commercially available. Non-available antibodies were conjugated to lanthanide metals using Maxpar X8 antibody labelling kit according to the manufacturer protocol (version 10). The antibody cocktail used is listed in Suppl. Table S8 
G6B Immunohistochemistry
Sections of formalin fixed and paraffin embedded (FFPE) bone marrow trephine biopsies were processed as follows: paraffin removed, antigen retrieval performed using citrate (Roche Cell Conditioning 2 Cat#950-123) pre-treatment for 30 minutes, washed and incubated with G6B
antibody diluted 1:100 in Ventana's DISCOVERY antibody diluent (Roche Cat#760-108) for 60 minutes at room temperature. Secondary detection was performed using UltraMap DAB anti-Ms HRP detection kit (Roche #760-152) for 16 minutes and slides counterstained with hematoxylin (Roche #760-2021) for 4 minutes and Bluing reagent (Roche #760-2037) for 4 minutes.
Sorting G6B+ and G6B-HSPCs for JAK2V617F qRT-PCR
For each experiment, MNCs from myelofibrosis patients and healthy donor controls were thawed and combined 1:1 in FACS buffer prior to antibody staining as described above. 50 G6B+ and G6B-cells were sorted into each well of a 96-well PCR plate (10 replicates per population for each experiment), containing CellsDirect One-Step qRT-PCR kit 2X Reaction Buffer and SuperScript III RT/Platinum Taq Mix (Thermo Fisher Cat#11753100), Ambion SUPERase-In RNase inhibitor (Thermo Fisher Cat#AM2694), TE buffer, JAK2 forward and reverse primers and wild-type and JAK2V617F-specific probe mix (see Key Resources Table) . RT and PCR were performed as per the kit protocol with 18 pre-amplification cycles then diluted 5x in TE buffer. Taqman RT-PCR was performed in a 20 µL reaction volume using 4 µL of the diluted cDNA, Taqman Fast Advance Mastermix (Thermo Fisher Cat#4444556) and the primers/probes as detailed in the Key Resources Table. Custom Taqman assays were designed as previously described (Moliterno et al., 2006) using RT-PCR primers flanking the mutant region plus two Taqman PCR probes specific for the normal or mutant sequence. An
Applied Biosystems 7500 Fast Real-Type PCR system was used with the default PCR conditions, with each replicate run in duplicate. Intra-assay replicates varying more than 5% were excluded.
10x Genomics single-cell RNA sequencing data pre-processing Sequencing data in the binary base call (BCL) format were demultiplexed. Unique molecular identifier (UMI) counts for given genes were obtained by aligning FASTQ files to the human reference genome (GRCh38) using Cell Ranger software (version 2.0.0) from 10x Genomics.
CellRanger "count" pipeline results from each of individual libraries from three patients and two healthy donors were then aggregated using default parameters to generate a gene count matrix based on CellRanger "aggr" standard pipeline. The UMI counts (> 1,000 and ≤ limited maximum UMIs), the number of detected genes (> 500 and ≤ limited maximum number of detected genes) and the percentage of mitochondrial gene expression (< 10%) per cell used as the cut-off criteria described in Suppl. Table 3 . Following these filters, 47,804 cells passed quality control for the whole sample aggregation. We excluded 617 out of 48,421 cells from further analyses. We scaled UMI counts by the total library size multiplied by 10,000. The normalized expression values were then log transformed. We regressed out the unwanted source of variation (library size, percentage of 22 mitochondrial genes and batches from patients and healthy donors) from gene expression values by applying the linear regression model using the limma package (Ritchie et al., 2015) .
Bioinformatics Analysis and R Code
Methods under submission; can be requested from supat.thongjuea@ndcls.ox.ac.uk
Quantification and Statistical Analysis Flow cytometry and CyTOF data analysis
Flow cytometry data was analysed using FlowJo software (v10.5.3). Summary charts and associated statistical analyses were performed using GraphPad Prism (v8.1.0). Helios CyTOF Software (v6.7) was used for processing of FCS 3.0 files, normalization to EQ Beads, concatenation of multiple files and debarcoding. Data was then analysed and histograms and viSNE plots generated using CytoBank.org.
Statistical tests used, numbers of replicates and definitions of statistical significance are described in the relevant figure legends. All bar charts show mean + standard error of the mean and were generated using GraphPad Prism (v.8.1.0).
Data and software availability
Data has been submitted to GEO (Accession Number will be provided on publication). TARGET-Seq single cell RNA-sequencing data is available at GEO: GSE105454. The Shiny application for visualisation of the data from patients and healthy donors in this study is available at https://github.com/supattlab/SingCellR-myelofibrosis.
Supplemental Information
Suppl. Figure 2A ). Violin plots: x-axis -cluster ID. For controls, cluster 1 -HSPC 1; cluster 2 -HSPC 2; cluster 3 -HSPC 3; cluster 4 -myeloid; cluster 5 -HSPC 4; cluster 6 -erythroid; cluster 7 -erythroid/megakaryocyte; cluster 8 -lymphoid. For myelofibrosis, cluster 1 -HSPC 1; cluster 2 -HSPC 2; cluster 3 -HSPC 3; cluster 4 -erythroid; cluster 5 -lymphoid; cluster 6 -myeloid; cluster 7 -megakaryocyte progenitor 1; cluster 8 -megakaryocyte progenitor 2 (see also Suppl. Tables 4 and 5 ). Y-axis -log(Normalized UMI).
Abbreviations -Mye -myeloid; Lym -lymphoid; Ery -erythoid; MK -megakaryocyte.
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